Investors

We are transforming the science of medical imaging, creating a new world of possibilities for the biopharmaceutical industry and healthcare professionals alike. By accelerating the development of new therapies and improving the diagnosis and treatment of serious diseases, we deliver value for our investors and partners, as well as those whose lives we touch.

We deliver on a global scale.  Our reach stretches worldwide, from the USA, the world’s largest healthcare market, across Europe, and into Asia, an increasingly important region for clinical development and patient care. This global presence is reflected by our work with world-leading pharmaceutical and biotechnology companies and contract research organizations, as well as our partnerships with multinational imaging specialist Canon and the world’s largest phase I clinical trial organization, START.

The combination of Median’s ground-breaking technology and world-class expertise perfectly positions us to revolutionize the field of medical imaging, transforming data generation, management, and access all around the world.  Benefiting patients, health professionals, our partners and investors.

Board of directors and management team

Experienced leadership

Median’s management team has extensive experience of the imaging, patient care and clinical trial sectors.  Our Board of Directors brings significant industry, financial and strategic expertise to the company.

Major shareholders

Stock market data

Median Technologies is listed on Euronext Growth

(ISIN: FR0011049824, ticker: ALMDT)

Stock market data

Place of listing

Euronext Growth

Number of shares

11,688,069
(July 31, 2017)

Share code

Name
Median Technologies

Mnemonic
ALMDT

ISIN Code
FR0011049824

Shareholding structure (June 30, 2017)

Non-nominative information as at June 22nd, 2017

  • FURUI Medical Science Company Luxembourg 12.9%
  • DFJ Funds managed by ePlanet Capital 11.69%
  • Abingworth Bioequities master fund LTD (nominative and non nominative 11.41%
  • Canon Inc 8.23%
  • Growth equity opportunities fund III LLC managed by NEA 8.2%
  • Funds managed by Idinvest Partners (nominative and non nominative 6.31%
  • Auriga Ventures II (nominative and non nominative 5.93%
  • Founders 5.13%
  • Others 30.51%
    • Others include:
    • Acuta Capital
    • Polar Capital
    • HBM
    • Pine River
    • ACP Cell Quattro

Financial agenda

  • 2017
    • Publication of our half-year results 2017: after closure on October 10, 2017
    • Publication of our annual results for 2016: after closure on April 12, 2017
  •  2016
    • Publication of our half-year results 2016: after closure on October 12, 2016
    • Publication of our annual results for 2015: after closure on April 12, 2016
  • 2015
    • Publication of our half-year results 2015: after closure on October 5, 2015
    • Publication of our annual results for 2014: after closure on April 15, 2015
  • 2014
    • Publication of our half-year results 2014: after closure on October 9, 2014
    • Publication of our annual results for 2013: after closure on April 28, 2014
  • 2013
    • Publication of our half-year results 2013: after closure on October 10, 2013
    • Publication of our annual results for 2012: after closure on April 10, 2013
  • 2012
    • Publication of our half-year results 2012: after closure on October 8, 2012
    • Publication of our annual results for 2011: after closure on February 16, 2012
  • 2011
    • Publication of our half-year results 2011: after closure on September 16, 2011

Investor contacts

in-contact-1

Median Technologies

Fredrik Brag
investor@mediantechnologies.com
tel: +33 4 93 333 777

actifin

Actifin Financial Communication
actifin.fr

Ghislaine Gasparetto
ggasparetto@actifin.fr
Tel +33 1 56 88 11 22

in-contact-3

Aurel BGC Listing Sponsor
www.aurel-bgc.com/fr

Nicolas Martin
NMartin@aurel-bgc.com
Tel +33 1 53 89 73 17

Cookies help us deliver our services. By using our services, you agree to our use of cookies.